Fact sheet: Phoenix SM Schroder Med DiscoveryPn

Fund information
Fund name
Phoenix SM Schroder Medical Discovery Pn
Fund manager company
Phoenix Life Limited
Fund type
Pension Fund
Fund managers
  • John Bowlersince 30/03/2004
Underlying fund
Schroder Global Healthcare
Fund objective
The fund's investment objective is to achieve capital growth. The fund will invest in healthcare, medical services and related products and companies on a world wide basis. Investment will be in directly held transferable securities. The fund may also invest in collective investment schemes, warrants and money market instruments.
Benchmark
  • MSCI ACWI Free Healthcare
Investment style
No data available.
Investment method
No data available.
Quick stats
1 Year return
10.2%
1 Year rank in sector
185/513
Sector
PN Specialist
Yield
-
Fund size
£0m
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
122
Bid price
309.2
Offer price
325.4
Top in this sector
Fund name1 Year
OMW Neptune Rus + Grtr Rus39.8%
ReAssure AL NptRu&GtrRus Pn39.2%
L&G Nep Russia&Gtr Russia Pn39%
Scot Eq JPM Emg Eur Eq Pn36.3%
OMW InvescoPerpetualEmgEurpn34.6%
...more in PN Specialist

Performance snapshot

Holdings snapshot

  • USA61.7%
    Switzerland7.6%
    UK6.5%
    Japan5.1%
    Germany4.4%
  • Health Care91.5%
    Money Market3.9%
    Basic Materials3.1%
    Consumer Services0.8%
    Industrials0.8%
  • US Equities61.7%
    Swiss Equities7.6%
    UK Equities6.5%
    Japanese Equities5.1%
    German Equities4.4%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund-0.2%-3.6%2.6%10.2%45.6%120.9%
Sector-0.9%-0.9%6%8.2%20.2%40.8%
Rank within sector190 / 546462 / 544334 / 531185 / 51338 / 38618 / 317
Quartile2nd4th3rd2nd1st1st
Calendar performance
 YTD - 20162015201420132012
Fund4.8%9.2%25.6%35.1%10.1%
Sector8.2%2%7.2%11%7.7%
Rank within sector302 / 51435 / 45020 / 38810 / 357113 / 318
Quartile3rd1st1st1st2nd
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
3.57
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
1.69
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.81
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
13.16
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
9.32
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
0.79
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.59
Price movement
52 week high342.3
52 week low264.9
Current bid price309.2
Current offer price325.4
Current mid price-
Region
1USA61.73%
2Switzerland7.58%
3UK6.48%
4Japan5.14%
5Germany4.4%
6Money Market3.86%
7France2.91%
8Israel2.78%
9Denmark1.26%
Industry sector
1Health Care91.49%
2Money Market3.86%
3Basic Materials3.08%
4Consumer Services0.8%
5Industrials0.77%
6Derivatives-0%
Asset type
1US Equities61.73%
2Swiss Equities7.58%
3UK Equities6.48%
4Japanese Equities5.14%
5German Equities4.4%
6Money Market3.86%
7French Equities2.91%
8Israeli Equities2.78%
9Danish Equities1.26%
Individual holdings
1JOHNSON & JOHNSON6.79%
2UNITEDHEALTH GROUP INC5.65%
3MEDTRONIC PLC4.55%
4AMGEN INC4.1%
5CELGENE CORP3.83%
6ROCHE HLDG AG3.8%
7PFIZER INC3.5%
8MERCK & CO INC(NEW)3.37%
9BAYER AG3.08%
Management
Fund manager group
Phoenix Life Limited
Fund manager company
Phoenix Life Limited
Fund type
Pension Fund
Fund objective
The fund's investment objective is to achieve capital growth. The fund will invest in healthcare, medical services and related products and companies on a world wide basis. Investment will be in directly held transferable securities. The fund may also invest in collective investment schemes, warrants and money market instruments.
Benchmark
  • MSCI ACWI Free Healthcare
Investment style
No data available.
Investment method
No data available.
Fund managers
NameSinceBiography
John Bowler30/03/2004John Joined Schroders in 2003.Investment career commenced in 1994.Currently Global Sector Specialist with responsibility for the healthcare sector and manager of the Schroder Medical Discovery Fund, as well as having primary research responsibility for Pan-European pharmaceuticals. Based in London John joined Schroders from AXA Investment Managers, where he had worked since 1998 in a global healthcare research role. He was voted top buy-side analyst for the pharmaceutical and healthcare sector in the Institutional Investor Pan European Equity survey in 2002.Before this, John worked at State Street Research & Management from 1997 as a fund manager / analyst.Earlier, John joined Hill Samuel Asset Management in 1994 as a graduate trainee, later becoming a junior fund manager for UK equities.Institute of Investment Management and Research (IIMR) qualified. Member of the CFA Society of the UK (CFA UK). PhD in Biochemistry & Physiology, from the University of Manchester. Degree in Biology from the University of Manchester.
Compliance
No data available.
Domicile
No data available.
Fund for sale in
United Kingdom
Phoenix SM Schroder Medical Discovery Pn
Initial charge-
Annual charge-
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)-
Bid price309.2
Offer price325.4
Mid price-
CurrencyGBX
Price updated05/12/2016
Type-
Institutional or retail classRetail
Domicile-
Citi codeS463
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.